期刊
NUTRIENTS
卷 14, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/nu14081575
关键词
autoimmune diseases; Coimbra protocol; high-dose therapy; multiple sclerosis; parathyroid hormone (PTH); vitamin D receptor (VDR); vitamin D; vitiligo; safety; single nucleotide polymorphisms (SNPs)
The study shows that high doses of orally applied vitamin D3 for the treatment of autoimmune diseases are safe with proper supervision by experienced physicians. The participants in the study did not experience hypercalcemia or impaired renal function while following a low-calcium diet and adequate fluid intake.
Background: In 2013, the group of Cicero Coimbra, Brazil, reported the clinical efficacy of high doses of vitamin D3 in patients suffering from autoimmune skin disorders (Coimbra protocol, CP). However, hypercalcemia and the subsequent impaired renal function may be major concerns raised against this protocol. Methods: We report for the first time for a broad spectrum of autoimmune diseases in 319 patients (mean age (+/- SD) 43.3 +/- 14.6 years, 65.5% female, 34.5% male) safety data for high doses of orally applied vitamin D3 (treatment period: up to 3.5 years) accompanied by a strict low-calcium diet and regular daily fluid intake of at least 2.5 L. Results: Mean vitamin D3 dose was 35,291 +/- 21,791 IU per day. The measurement of more than 6100 single relevant laboratory parameters showed all mean values (+/- SD) within the normal range for total serum calcium (2.4 +/- 0.1 mmol/L), serum creatinine (0.8 +/- 0.2 mg/dL), serum creatinine associated estimated GFR (92.5 +/- 17.3 mL/min), serum cystatin C (0.88 +/- 0.19 mg/L), serum TSH (1.8 +/- 1 mIU/L), and for 24 h urinary calcium secretion (6.9 +/- 3.3 mmol/24 h). We found a very weak relationship between the dosage of oral vitamin D3 and the subsequent calcium levels, both in serum and in urinary excretion over 24 h, respectively. Conclusions: Our data show the reliable safety of the CP in autoimmune patients under appropriate supervision by experienced physicians.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据